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Abstract
We evaluate by simulation three model-based methods to test the influence of a single nucleotide polymorphism on a pharmacokinetic
parameter of a drug: ANOVA on the empirical Bayes estimates of the individual parameters, likelihood ratio test between models
with and without genetic covariate, and Wald tests on the parameters of the model with covariate. Analyses are performed using the
FO and FOCE method implemented in the NONMEM software. We compare several approaches for model selection based on tests
and global criteria. We illustrate the results with pharmacokinetic data on indinavir from HIV-positive patients included in
COPHAR 2-ANRS 111 to study the gene effect prospectively. Only the tests based on the EBE obtain an empirical type I error close
to the expected 5 . The approximation made with the FO algorithm results in a significant inflation of the type I error of the LRT%
and Wald tests.
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INTRODUCTION
Pharmacokinetics studies the time course of a drug in the body ( ). The variability in theGabrielsson and Weiner, 1999
pharmacokinetics of drugs when administered to different subjects is often important and should be studied to improve the use of drugs,
avoid toxic events and allow individualization of therapy. The contribution of genetic factors to this variability is potentially important (
). Some genes have already been the subject of much attention, for example the ABCB1 gene coding for the PLicinio and Wong, 2002
glycoprotein (P-gP) found on the main exchange barriers ( ). The involvement of this protein in drug absorptionMarzolini et al., 2003
processes has been demonstrated directly in animals and indirectly in humans. For example, co-administration of paclitaxel and
cyclosporine, respectively a substrate and an inhibitor of P-gP, has been shown to increase the bioavailability of paclitaxel (Meerum et al.,
). More recently, Yamaguchi and colleagues demonstrated the impact of ABCB1 polymorphism on paclitaxel pharmacokinetics in1999
patients with ovarian cancer ( ). The ABCB1 gene is composed of 209 kb ( ), and to date 28Yamaguchi et al., 2006 Bodor et al., 2005
polymorphisms concerning a nucleotide modification have been described, including several with potential clinical impact (Sakaeda et al.,
). In the present study, we consider data from patients treated with indinavir in the COPHAR2-ANRS11 study investigating the2002
benefit of early therapeutic drug monitoring in anti-retroviral therapy. Since the ABCB1 genetic polymorphism was found to have an
influence on the pharmacokinetics of protease inhibitors ( ), patients were genotyped for two exons (exon 21 and 26) ofFellay et al., 2002
the ABCB1 gene.
The influence of genetic polymorphism on concentration data is usually analysed using non-compartmental analysis (NCA). The area
under the concentration  time curve as well as model-independent parameters are calculated for each individual concentration profileversus
using, for example, the log-trapezoidal method ( ) and individual pharmacokinetic (or PK) parameters areGabrielsson and Weiner, 1999
then compared between the different genotype groups using ANOVA ( ). More sophisticated approaches usingInomata et al., 2005
nonlinear PK models in individual regression ( ) or mixed effects models ( ) have also been applied toMin et al., 2004 Taguchi et al., 2006
genetic data in PK studies. Nonlinear mixed effects models (NLMEM) require fewer blood samples in each patient and can be important in
special populations such as patients with acute disease or neonates, for whom extensive sampling is obviously impractical.
Various methods can be used to include pharmacogenetic information in NLMEM ( ). Empirical Bayes estimatesComets et al., 2007
(EBE) of the individual parameters can be computed from the fit of a model with no covariate and compared between the different
genotype groups with an ANOVA to test the genetic polymorphism effect ( ). Another approach is to performHenningsson et al., 2005
Wald tests on the estimates of the gene effect coefficients in the covariate model ( ), while stepwise model building isKerbusch et al., 2003
frequently based on the comparison of models with and without gene effect using the likelihood ratio test (LRT) ( ).Mamiya et al., 2000
The first purpose of this work is to assess the statistical properties of these three different strategies to test for a gene effect through a
simulation study. The setting for the simulation study is based on the COPHAR2-ANRS11 study. We have also taken the impact of
estimation methods into account, comparing results from the FO and FOCE methods implemented in the NONMEM (nonlinear mixed
effect model) software ( ). The type I error of the tests is evaluated using simulations under the null hypothesis H  ofSheiner and Beal, 1998 0
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no gene effect for two designs (40 patients as in the study, 200 patients to examine the influence of sample size), while the power is
compared using simulations under an alternative hypothesis H .1
In the same simulation study, we also examine model selection strategies, in which the aim is to choose the best covariate model for
the gene effect. We compare test-based strategies with general selection criteria that have been proposed, like the Bayes information
criterion (BIC) ( ) and the Akaike information criterion (AIC) ( ). According to the parsimony principle, theseSchwartz, 1978 Akaike, 1974
criteria penalize the log-likelihood by the number of model parameters which limits overfitting. Alternative criteria derived from the AIC
have been developed in order to deal with small samples or to improve AIC asymptotic consistency. The properties of these criteria have
been studied in generalized linear models ( ), like the trend to select an over-parameterized model with AICBurnham and Anderson, 2002
and under-parameterized model with BIC. AIC and BIC have been widely used in population PK and PK/PD studies during the past
decade. In the present paper, we compare through a simulation study their properties for nonlinear mixed effects model selection.
In this paper, we first introduce the model, the notations, the different tests and model building strategies under study and the
estimation methods. Then we describe the case study and the simulation study based on its design. Next we present the results of the
simulation study and the application to the real data. Finally we discuss our findings.
METHODS
Model and notations
Let the function  denote the PK model, which depends nonlinearly on its parameters . The concentration  at time  for subject f θ y  i ,  j t  i ,  j i
1, ,  and measurement   1, , is given by:= … N j = … n  i
where is the vector of  PK parameters for the i  individual and  the residual error, assumed to be normally distributed with zero θi P th  εi ,  j
mean and variance  . Here we assume a proportional error model: σi ,  j 2
We assume a multivariate log-normal distribution for the vector of individual parameters, are then expressed as: θi
with  the vector of fixed effects and the vector of random effects. The random effects are assumed to be independent of  andμ b  i b  i  εi ,  j
normally distributed with zero mean and variance matrix . In this work, we used a diagonal  with interindividual variance of the pΩ Ω th
parameter  , however an unspecified positive definite matrix can be assumed.ω2 p
For simplicity, let us assume that our aim is to detect the effect of a single nucleotide polymorphism (SNP) on one PK parameter, for
instance the p  component of . Let C denote the wild-type allele and T the mutant. An individual can be one of three genotypes (eg.th ;  θ θp
CC for the wild-type homozygotes, CT or TT). Let denote the genotype for subject i, and let ( )  , or for  CC, CT orG  i β G  i =  β0  β1  β2 G  i =
TT, respectively. We write the model for the genetic polymorphism effect in subject  as:i
We assume that CC is the reference class so that  1. β0 =
Let model M  be the model in the absence of genetic polymorphism effect:       1 , (CC  CT  TT). There are threebase {β0 = β1 = β2 = } = =
models including the gene effect as a covariate: a complete model where the mean of the parameter is different in the three groups, M : mult {
  1,     1 , (CC  CT  TT) and two reduced models, M :     1,   1 , (CC  CT  TT) and M :   1,   β0 = β1 ≠ β2 ≠ } ≠ ≠ recessive {β0 = β1 = β2 ≠ } = ≠ dominant {β0 = β1 = β2
 1 , (CC  CT  TT).≠ } ≠ =
In the following,  corresponds to the model log-likelihood, represents the number of population model parameters (mean PKL P  pop
parameters, covariate coefficients, variances and error model parameters),  the sample size and the total number of observations. TheN n  tot
standard error and covariance of the parameter estimates are abbreviated by SE and cov, respectively.
Tests for genetic polymorphism effect
In this section, we examine different tests based on NLMEM that can be used to test the existence of a genetic polymorphism effect on
one parameter of a PK population model.
Analysis of variance (ANOVA)
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Data are analysed with a model with no covariates (M ) and Empirical Bayes estimates (EBE) of the individual PK parameters arebase
computed. A one-way analysis of variance is used to detect differences in these EBE between the different genetic groups.
Wald test
The data are analysed using the complete model M , and the significance of the parameters is assessed using a global Wald test:mult
where  represents the variance covariance matrix of parameters   and  . The statistic  is compared to the critical value of a Σ β 1 β 2 W χ2
with two degrees of freedom.
Likelihood Ratio Test (LRT)
The third test relies on the comparison between the model with no covariate effect M  and the complete model M . These twobase mult
nested models are compared with the LRT. The test statistic  2(    ) is compared with a  with two degrees of freedomS  LR = − L base − L  mult χ2
where and are the log-likelihood of M  and M  respectively. The two degrees of freedom correspond to the difference in theL  base L  mult base mult
number of population parameters between the two models.
Strategies for model building
In this section, we examine a second aspect, which is model selection. The different strategies under study provide decision rules for
covariate inclusion in order to get the best model.  represents in a diagram the decision path of the three strategies using tests.Figure 1
When performing multiple tests, a correction which preserves the false discovery rate is used ( ).Benjamini and Hochberg, 1995
Selection based on EBE
If the test that compares means of EBE obtained with M  between CC, CT and TT using an ANOVA is significant, the means of thebase
EBE obtained with M  are compared between the CC and the CT, on one hand, and between the CT and the TT, on the other hand, usingbase
t-tests. If none or one test is significant, the one with the lower p-value leads to model selection, or else M  is selected. For example, ifmult
the test comparing the CC to the CT has the lower p-value, M  is chosen.dominant
If the global test is non-significant, the means of the EBE obtained with M  are compared using t-tests opposing: i) the CC to the CTbase
and TT put together, and ii) the TT to the CT and CC put together. If one or both tests are significant, the model corresponding to the test
with the lower p-value is selected, else M  is selected. For example if the test comparing the CC to the group formed by the CT and thebase
TT has the lower p-value, M  is chosen.dominant
Selection based on Wald test
If the global Wald test comparing  to a  with two degrees of freedom is significant, two Wald tests on coefficients estimated in MW χ2
 are then realized; comparing both  and  with a  with one degree of freedom. If none or one test is significant, the one withmult χ2
the lower p-value leads to model selection, or else M  is kept. As an example, if  has the lower p-value, M  is chosen.mult dominant
If the global test is non-significant, data are analysed using the two models with the gene effect in two classes and Wald tests are
performed on the coefficients estimated in M  and M . The two statistics  and  are compared with a  with one degreerecessive donminant χ2
of freedom. If one or both tests are significant, the model is chosen based on the test with the lower p-value, or else M  is conserved. Bybase
way of example, if  has the lower p-value, M  is selected.dominant
Selection based on LRT
If the LRT comparing M  with M  is significant, then two LRT are performed comparing M  with the nested models Mbase mult mult dominant
and M . If none or one test is significant, the test with the higher p-value leads the model choice, or else M  is selected. As anrecessive mult
example, if the test comparing M  with M  obtains the higher p-value, M  is selected.mult dominant dominant
If the global test is non-significant, M  is compared with M  and M  using LRT. Then, if one or both tests are significant,base dominant recessive
the model is chosen based on the test with the lower p-value, or else M  is selected. For example, if the test comparing M  to Mbase base dominant
obtains the lower p-value, M  is selected.dominant
Selection based on information criteria
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As an alternative, criteria such as AIC or BIC can be used for model selection. Here, the model with the lowest criterion is chosen.
Both of these criteria balance the log-likelihood with the number of parameters in the population model. According the parsimony
principle, a simpler model is preferred for equivalent information gain. The AIC is written as:
The expression of the BIC involves the total number of observations:
The BIC is related to the Bayes factor which is a measure of the strength of evidence in favour of a given model and can thus be used
to quantify model uncertainty.
Other criteria have been defined, derived from those above: the corrected AIC (AICc) defined by Akaike for small samples i.e. when n
/ < 40 ( ) and the consistent AIC (CAIC) ( ). They are derived from AIC and involve the total number tot P  pop Sugiura, 1978 Bozdogan, 1987
of observations:
Another formulation for BIC has also been proposed, BICc, where is replaced by the number of subjects ( ):n  tot Raftery, 1995
Estimation methods
In NLMEM, the parameters and their standard error are mainly estimated using maximum likelihood. However the likelihood function
for these models is expressed as an integral and has no analytical solution. Specific algorithms have therefore been proposed to perform
the maximization. The approach most frequently used relies on first-order approximations of the likelihood function. This approach has
been implemented in the NONMEM software version V which is the most frequently used software in PK/PD analyses. In NONMEM two
approximations can be used: the first-order method (FO), relying on a first-order linearization of the likelihood function around  0, andb  i =
the first-order conditional estimation method (FOCE), relying on a first-order linearization of the likelihood function around the estimates
of the individual random effects. Although the FO method suffers from bias and lack of precision it is still frequently used as it is faster
and has less convergence problems than FOCE. In this paper, we compare both estimation methods. More precisely, we use the FOCE
with interaction method, allowing possible interaction between inter- and intra-variability.
Real data and simulation study
Real data
We illustrate the different approaches on data from a PK sub-study of the COPHAR 2-ANRS 111 study, a multicentre
non-comparative pilot trial of early therapeutic drug monitoring in HIV positive patients na ve of treatment. The objective of the trial wasï
to assess the benefit of a pharmacological intervention after measurement of trough plasma concentrations of protease inhibitors (Mentr  eté
). We focus on the PK sub-study from the group of patients receiving indinavir boosted with ritonavir. Patients were genotypedal., 2005
for the ABCB1 exons 21 and 26 to investigate genetic polymorphism impact on pharmacokinetics of the protease inhibitors, which are
well-known substrates of the P-gp ( ).Fellay et al., 2002
Forty-two patients were included, one patient withdrew from the study and one switched to another protease inhibitor during the first
week of treatment. We therefore obtained PK data for 40 patients (27 men, 13 women) with an average age of 36.5 years. PK profiles were
determined at 1, 3, 6 and 12 h after administration of the drug at a date two weeks after the treatment onset. One patient had missing
information for the two genotypes, and ABCB1 exon 26 genotype was missing in two other patients.
Simulated data
The design used in the simulation mimics that of the application data set. We simulate PK studies of N  40 (equivalent to the=
application sample size) and N  200 patients with four samples (1, 3, 6, 12 h after dose) at steady state. The same bid doses of 400 mg for=
indinavir and 100 mg for ritonavir are assumed for all patients. The concentrations are simulated using the steady-state one-compartment
model with first-order absorption and elimination that was used to model the indinavir concentrations in the COPHAR 1-ANRS 102 study
( ):Brendel et al., 2005
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where  represents the bioavailability, the absorption rate,  the elimination rate,  the volume of distribution and   12 h the timeF k  a k V τ =
between two doses. We use the following population parameters: /   102 L with interindividual variability  41.3 ,  1.4 hV F = ω  V = % k  a = 1−
with  113 ,   0.2 h  with  26.4  obtained with a preliminary analysis of the real data using the FO method in NONMEMω
  k
 a
= % k = 1− ω  k = %
and a residual error of 20 . The measurements below the quantification limit (BQL) are treated in the analysis using a standard approach:%
the first value in a series of BQL was set to LOQ/2 and the remaining values were discarded ( ).Beal, 2005
Under H , 1000 data sets are simulated with a design of N  40 patients and 1000 with a design of N  200 patients. We simulate a0 = =
combination of SNP on two exons located on the same chromosome. The bioavailability  is assumed to depend on the diplotype. BecauseF
the model is parameterized as / , and , this is equivalent to assuming that /  depends on the diplotype. The distribution of the exonsV F k  a k V F
mimics that of exon 26 and exon 21 of the ABCB1 gene as reported by Sakaeda and colleagues ( )  we note C and GSakaeda et al., 2002 –
respectively the wild-type allele for the 2 exons and T the mutant allele. With those properties, for data sets with 40 patients we expect on
average 9 individuals with a CC genotype, 18 with CT genotype and 13 with TT genotype for exon 26.
Under the alternative hypothesis, we assume the following effect of the two polymorphisms (modified from ), where equation (4) G  26i
denotes the genotype for the exon 26 and the genotype for the exon 21:G  21i
where (G ) is ,  or  if  CC, CT or TT as previously and ( ) is ,  or  if  GG, GT or TT. Under H  we set (Gβ   26i β0 β1 β2 = δ G  21i δ0 δ1 δ2 G  21i = 1 β  
)  1, 1.2, 1.6 and ( )  1, 1.1, 1.3. These values were chosen to provide a good power for the detection of one SNP effect in the 26 = δ G  21 =
context of the simulations while remaining consistent with results found in the literature concerning the effect of ABCB1 polymorphism.
With those genetic coefficient effects and the distribution from the literature, we simulated 100 data sets with the N  40 design. When we=
computed the ( / ) EBE from M  and performed bilateral t-tests to compare the wild homozygotes and the mutant homozygotes forV F   i base
the exon 26, we obtained a power of 80  ( ).% Machin et al., 1997
The simulation of each data set is performed as follows. The set of possible genotypes for exon 26 and exon 21 is S CC-GG, CC-GT,={
CC-TT, CT-GG, CT-GT, CT-TT, TT-GG, TT-GT, TT-TT  with corresponding simulated frequencies f 0.2, 0.02, 0.02, 0.05, 0.38, 0.05,} ={
0.04, 0.04, 0.2 . For each individual the genotypes are drawn from this distribution. Under H , both genotypes condition the value of the} 1
fixed effects for V/F according to . Then we simulate a random effect vector from a normal distribution (0, ), yielding theequation 11 b  i N Ω
individual parameters vector   according to . The concentrations are computed using these parameters. Finally we add aθ i equation 3
residual error, generated from a normal distribution (0,   ( ,  )), to each predicted concentration to obtain the simulatedN σ 2 f θ t  i ,  j
concentration.
Simulations were performed using the statistical software R (R ) running under Linux (Red Hat 9.0).Development Core Team 2006
Evaluation of the tests for genetic polymorphism effect
In the first step, each of the three tests presented above is applied to detect the effect of the exon 26 polymorphism on the 1000 data
sets simulated under H  for each design (40 and 200 patients). Tests are performed on estimations obtained for each data set using FO and0
FOCE in NONMEM. The type I error for each analysis is defined as the percentage of data sets where the corresponding test was
significant. The expected prediction interval with 1000 simulations and a value of 5  is 3.7; 6.3 . To ensure a type I error of 5 , we% [ ] %
define a correction threshold as the 5  percentile of the distribution of the p-values of the test under H .th 0
In the second step, for the design with 40 patients, the same tests are performed using the 1000 data sets simulated under H . The1
power is defined as the percentage of data sets where the corresponding test was significant. We use the corrected threshold to compute the
corrected powers. This allows comparison of the different tests even if the type I error is different from 5 .%
Data sets with a group defined by the genotype for exon 26 with less than two patients are discarded from the analysis. It should be
emphasized that the number of simulated data sets for which the tests can be applied are often less than 1000. Indeed, the algorithms FO
and FOCE used in the NONMEM software are sometimes unable to converge on a data set. In that case, estimates are not available and no
tests can be applied. Similarly, even when the linearization algorithms achieve convergence, the variance covariance matrix is not always
available. More precisely, to perform the ANOVA on the EBE only the convergence of model M  is required with or without the SEbase
estimates. The Wald test requires the parameter estimation error to compute the test statistics, thus not only the convergence of model M
 is required but the variance covariance matrix must also be available. The convergence of both M  and M  is necessary to applymult base mult
the LRT but the covariance step is not needed to succeed. The three tests were also evaluated on a subset of data sets fulfilling all the
conditions listed in this paragraph using FO or FOCE.
Evaluation of the strategies for model building
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The different model building strategies described above based either on tests or selection criteria are evaluated on data sets with the N 
 40 design. Results are reported as the percentage of data sets for which each model of the exon 26 polymorphism effect is selected, and=
this with simulation under H  or under H . The correct model is M  under H  and M  under H . The results of the strategies obtained0 1 base 0 mult 1
by simulation under H  are not used to modify the strategies under H  as there are no simple correction methods for over-selecting0 1
covariate models under H .0
As for the evaluation of tests, the analyses are not always performed on the 1000 data sets. The conditions to perform model building
following an ANOVA are identical to those described for the test. To choose the best model using Wald tests, the convergence and the
covariance step are required for the three models including the gene effect. For the selection with the LRT, convergence of the four models
is required and for the criteria based selection, at least one model must have achieved convergence. The different strategies were also
evaluated on samples satisfying all conditions with FO and FOCE.
Application to real data
The indinavir concentrations are analysed with the same PK model as in the simulation study. The estimation method is chosen based
on performances in the simulation study. Both the exons 26 and 21 of the ABCB1 gene are investigated using the three tests and the eight
model building strategies.
RESULTS
Type I error and power of the detection tests
For the design with N  40, three simulated data sets (one under H  and 2 under H ) are discarded from the analysis due to a group of= 0 1
less than two patients with the TT genotype. Also, FOCE encounters many more convergence problems than FO; , the number of dataK
sets among the 1000 on which the test is performed, is always lower with FOCE.
Type I error estimates of the three tests performed are shown in . For the design with N  40, the ANOVA type I errors do notTable 1 =
significantly differ from 5  with both estimation algorithms. The LRT type I error estimates show a slight significant increase with FOCE%
and increase by ten times using FO. For the Wald test, there is a rather important significant increase for FOCE and again inflation by four
times with FO. For the design with 200 patients, the LRT attain a type I error non-significantly different from 5  and the Wald test still%
has an estimate slightly superior to the nominal level with FOCE. The large increase of the type I error remains the same with FO for the
LRT and the Wald test.
Estimates are given of the power of the tests using both estimation algorithms for the ANOVA, the Wald test and the LRT, for the
design with 40 patients, in . For each test and each estimation method, the corrected power is computed using the correspondingTable 2
empirical threshold in order to maintain a type I error of 5 . The corrected power for LRT and Wald tests based on the FO method were%
low, but the inflated type I error in these situations already show that this estimation method is poor. The powers for the ANOVA (using
FO or FOCE) and the LRT for FOCE are around 70 , but the power of the Wald approach for FOCE is much lower (25 ). We explored% %
the FOCE outputs to understand this last result. In fact, with the FOCE algorithm in NONMEM, we observe correlations between the
estimates of the gene effect coefficients and their estimation errors. This relationship leads to decreased values of the Wald statistic and
therefore reduces the power to detect a genetic polymorphism effect. The same results were obtained considering only the subset of data
sets fulfilling all convergence conditions for both FO and FOCE.
Model selection strategies
The results of the model selection strategies applied to the data sets simulated under H  with the design of 40 patients are presented in 0
. Again, the performances of the FO algorithm are unsatisfactory except for the strategies based on EBE. With FOCE, both modelTable 3
selection strategies based on EBE and LRT select the correct model M  in about 90  of instances whereas the Wald approach selects abase %
model with a gene effect in around 15  of the data sets. Using selection criteria, the AIC and AICc obtain the worst performances,%
selecting a model with a gene effect in 57.8  and 51.7  of the data sets respectively. BICc shows performance close to that of the% %
approach based on Wald tests, while CAIC (4.7 ) and BIC (6.7 ) select a model with a gene effect in about 5  of the data sets.% % %
The results on data sets with N  40 simulated under H  are given in . The results of the strategies using the LRT, Wald tests or= 1 Table 4
a criterion with the FO estimation method are not presented because of the poor properties under H . A model with a gene effect is0
selected for about 70  of the data sets using CAIC, for about 80  of the data sets using the different model-building strategies based on% %
tests or BIC, for about 90  of the data sets using BICc, and for about 99  of the data sets using AIC and AICc. However, for the latter,% %
the percentage of data sets where M  is not selected under H  is greater than 50 . Another noticeable result is that the model used tobase 0 %
simulate the data M  is seldom selected compared with the intermediate model M , which is chosen in 30 to 50  of the data setsmult recessive %
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using the different methods. The simulated value (  is low compared with ( , therefore if the model-building strategies succeed inβ1 β2
selecting a model with a gene effect, it is not always the correct one. The performances are similar using the sample of data sets for which
all conditions were put together with FO and FOCE.
 represents a summary of these results, placing each strategy on a bi-dimensional plan; the ability to select a model with aFigure 2
gene effect under H  versus the trend not to select M  under H . The CAIC is the test which has the best properties under H , but the1 base 0 0
BIC more often selects a model with covariate under H  while it is only slightly less conservative under H . We also note that the LRT, the1 0
BIC and the ANOVA are clustered together, and thus offer similar compromises.
Application
 represents a spaghetti plot of concentrations versus time for the 37 patients from the indinavir arm of the COPHAR2 study,Figure 3
sorted by genotype classes for exon 26. Concentrations show an important interindividual variability and only three patients were mutant
homozygotes for this polymorphism.
As the simulation study has shown poor performances with the FO algorithm, we estimated the model parameters using the FOCE
with interaction algorithm. Therefore, the estimates are different from the simulated values obtained in the preliminary analysis. In
addition, the estimate of the interindividual variability for k was very small and we fixed it to 0 (no variability). The model with no
covariate had an absorption constant of 0.8 h  with an important interindividual variability of 70.3 , an elimination constant of 0.2 h1− % 1−
and a volume of distribution of 99.3 L with an interindividual variability of 47 . All the estimation errors were below 20  for the fixed% %
effects and below 40  for the variances.%
For the influence of the ABCB1 exon 26 on the indinavir volume of distribution, the ANOVA and the LRT were non-significant (P =
0.7 and 0.2 respectively). The global Wald test obtained a p-value of 0.02, however the corrected threshold defined in the simulation study
for this test is 7.5.10 . The model with no covariate was chosen using the selection strategies based on the EBE, or on the LRT, using3−
CAIC, BIC and BICc, whereas the strategy based on Wald tests, AIC and AICc selected M . No influence of the ABCB1 exon 21 onrecessive
indinavir volume of distribution was detected using any of the tests or selection strategies under study.
DISCUSSION
In this work, we evaluate several statistical tests and model selection strategies using nonlinear mixed effects models to analyse the
impact of a genetic polymorphism on one PK parameter through simulation. We also study the impact of the estimation algorithms in
NONMEM, comparing the two first-order approximations most widely used FO and FOCE, which linearize the model function
respectively around the random effects equal to 0 and around the individual estimates of the random effects. Although the FO method has
been shown to suffer from various problems, it is still used because the FOCE algorithm is known for numerical difficulties and for its
slowness. Using the FO algorithm we observe unsatisfactory performances for all the tests and model selection strategies with the
exception of methods based on the EBE. The linearization of the likelihood function around the fixed effects leads to type I error inflation
( , , ).Comets and Mentr , 2001é W hlby et al., 2001ä Panhard and Mentr , 2005é
With FOCE, there is a significant increase in the type I error of the LRT and the Wald approach with a design including 40 patients.
This increase has already been described for the LRT ( , ) and has been also shown for theComets and Mentr , 2001é W hlby et al., 2001ä
Wald test ( ). The design with 200 patients is closer to asymptotic conditions and shows as expected a correctPanhard and Mentr , 2005é
type I error. Performing simulations under H  can be used to correct the threshold for the test under H  as we did in the present study. We0 1
observe a power around 70  for the tests using ANOVA and LRT which is close to the power of 80  expected from the simulation% %
settings. Of course if the study was designed specifically to detect a gene effect the sample size could be increased to ensure a higher
(more ethical) power. Our objective here was to compare different methods and we used the data from the COPHAR2-ANRS 111 trial to
provide the settings for the PK simulations, as we have analysed these data thereafter. The simulated effect of gene was chosen to be
consistent with the literature, though in the COPHAR2 trial the genotype distribution is slightly unbalanced. The reduced power of the
Wald approach and the unsatisfactory efficacy of the model selection strategy based on the Wald tests could result partly from a wrong
estimation of the standard errors due to the log-likelihood function linearization. Indeed, we observe with FOCE that in the simulations the
estimation errors are highly correlated to their estimates. Because the Wald statistic is based on the ratio of the estimates to the estimation
error, this could explain the poor performance of the Wald tests under H . Finally, FOCE met with convergence problems: on M  and M1 0
 which involved no mathematical complexities for N  40 under H , 35 (3.5 ) and 48 (4.8 ) runs did not achieve convergence,CCvsCTvsTT = 1 % %
either for numerical reasons or because they had to be terminated and we could not obtain an estimate of the variance-covariance matrix in
32 (3.2 ) and 38 (3.8 ) runs, respectively. This could have been improved partly by the use of different initial conditions, nonetheless the% %
results were identical using the sample of data sets fulfilling convergence conditions for the three tests using both estimation methods.
Among the different implementations of both algorithms available, we chose to use NONMEM as it is the most popular tool in the
pharmaceutical industry. Our results can be extended to the FO method implemented in SAS as it computes the same likelihood function
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up to a constant ( ), although it is not the same algorithm ( ). Similarly, FOCE with interaction and the nlme methodWang, 2007 Roe, 1997
with the varConstPower option implemented in Splus should give the same results, save for the lower accuracy of the Splus approximation
( , ). The simulations and analyses in the present paper have been performed using version 5.1 ofGirard and Mentr , 2005é Wang, 2007
NONMEM. A new version of NONMEM, version 6, has been released in December 2006, and was implemented in our department after
the major part of the analyses had already been run, so that we kept NONMEM 5.1 for this study. The FOCE routine in NONMEM 6 has
been rewritten and should provide more stable runs, which may reduce the convergence issues we have found in the present study.
However, in our preliminary results with using NONMEM 6 on a subset of the simulated datasets, an increased number of runs failed the
covariance-step. Rather than reporting partial results in the present study, we will investigate this matter in a subsequent work.
Model selection strategies based on tests have, to a certain extent, a high rate of false inclusion under H  (over 10 ) which could0 %
result from the unconnected multiple model comparisons. Further there is no simple way to correct the model selection under H  by taking1
into account the simulations under H . Consequently, we have to be cautious about assessing the performance under H  when the0 1
behaviour is poor under H .0
With respect to selection based on criteria, except for the performances of the BIC and the BICc not showing any trend to
conservatism, under H  our results agree with the literature. The acceptable performance of the CAIC has to be noted, as well as the very0
poor performance of AIC and AICc. Under H , there is a satisfactory weak selection of M  with a rather important representation of M1 base
. Indeed, in our simulation conditions, M  and M  are close and the power to detect a difference between these two models isrecessive recessive mult
much lower than the power to detect a difference between M  and M . As a side-note, in the Bayesian literature, it is usual also tobase mult
consider not only the best model (i.e. the model with the lowest criterion), but also models close to the best model ( ).Raftery, 1995
However in our study, the simulation model is rarely close in this sense to the best model.
Finally, in our study, for the design with 40 patients, the ANOVA on the EBE is the only test that maintained a 5  type I error, as well%
as a good power. It should be noted that we simulated a sufficient number of samples per patient with respect to the number of model
parameters. In sparse sample situations, regression to the mean is known to occur with EBE ( ), which couldPanhard and Mentr , 2005é
result in lower power to detect differences between genotype groups. We plan to test this hypothesis in a subsequent study with a sparse
design including only two samples per patient.
We also confirm that both AIC and AICc should not be used for model building but further studies are required to provide
recommendations on the other selection strategies. Regarding the estimation methods, if FO can still be used in covariate screening on the
EBE, one should avoid performing model building with the LRT or Wald tests based on results from this algorithm.
We illustrate the different approaches using data from the indinavir PK sub-study of the COPHAR2 ANRS-111 trial. The PK model
has already been described but no gene effect has been investigated using a population approach to date. The estimated parameters are in
accordance with estimations obtained in other studies ( , , ). The Wald test isCsajka et al., 2004 Goujard et al., 2005 Kappelhoff et al., 2005
the only test to detect an influence of ABCB1 exon 26 on the volume of distribution. Considering the corrected threshold provided by the
simulation study, we can probably ascribe this discrepant result to the inflated type I error. Similarly, it is the three strategies with the
highest percentage of data sets where M  is not selected under H  that select a model with the ABCB1 exon 26 polymorphism asbase 0
covariate. The polymorphism on the exon 26 of the ABCB1 gene has been shown to impact on plasma concentrations of nelfinavir,
another protease inhibitor ( ). However, this work agrees with another study ( ), where no effect ofFellay et al., 2002 Verstuyft et al., 2005
the polymorphisms from ABCB1 exon 26 and 21 on indinavir bioavailability was found.
Another extension of this work would be to simulate under H  various levels of the gene effects, which would provide more1
information on the relationship between the strength of the genetic polymorphism effect and the power. Designing an optimal sampling
schedule for testing a gene effect with a given power is also an interesting challenge and the extension of the PFIM software for design
optimization in the case of models with covariates could be used ( , ). Moreover in the geneticRetout and Mentre, 2003 Retout et al., 2007
framework one should keep in mind the complex pathway leading from DNA to metabolic activity, which is usually controlled by more
than one exon. Another perspective would therefore be to analyse the influence of the haplotypes ( ), since such aInnocentia et al., 2005
classification seems to be more relevant at the DNA level.
Pharmacogenetic studies using NLMEM have many advantages as fewer samples are required to estimate parameters with a biological
meaning. The current literature presents a wide array of methods for covariate selection using NLMEM. We show in this study that
methods using EBE are not only efficient in data exploration but also in model selection on data sets with enough samples per patient. We
also emphasize that using estimation algorithms based on likelihood linearization, LRT type I error is inflated, thus one has to perform
simulations or work with large data sets. Finally, the problems of the FO and FOCE algorithm in terms of convergence and bias are an
incentive to use more recent estimation methods ( ).Samson et al., 2007
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Figure 1
Decision path used to choose the best model for the selection strategies based on tests.
Figure 2
Percentage of data sets simulated under H  where the model with no gene effect (M ) is not selected versus the same percentage under H1 base 0
for the eight model selection strategies using FOCE for N  40. The vertical line corresponds to a value of 5  and the horizontal line to a= %
value of 80 .%
Figure 3
Indinavir concentrations (ng/mL) at steady state collected in the COPHAR2 ANRS-111 trial versus time, sorted by ABCB1 exon 26
genotypes. The plain lines correspond to a dose of 400 mg indinavir, the dashed lines correspond to 600 mg and the dotted lines correspond to
800 mg, all with a dose of 100 mg ritonavir bid.
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Table 1
Type I error for each test and for each algorithm.
Test Algorithm
N  40= N  200=
K Type I error ( )% K Type I error ( )%
ANOVA FO 997 5.9 1000 4.4
FOCE 986 5.6 982 5.1
Wald
FO 975 23.4* 984 10.3*
FOCE 924 11.7* 860 6.5*
LRT
FO 989 46.9* 977 54.0*
FOCE 964 7.9* 956 5.0
K is the number of data sets on which the test could be performed.
 
* Estimate significantly different from 5 .%
Table 2
Power for each test for N  40.=
Test Algorithm K Power ( )% Corrected power ( )%
ANOVA FO 995 69.8 66.5
FOCE 968 71.2 69.3
Wald FO 974 61.5 7.7
FOCE 905 57.2 24.7
LRT FO 958 90.2 48.7
FOCE 947 78.7 71.0
K is the number of data sets on which the test could be performed.
The corrected power was obtained using the fifth percentile of the empirical distribution of the test statistic under H  as the cut-off value for the test.0
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Table 3
Percentage of data sets simulated under H  with a design of N  40 for which each model is selected.0 =
Method Algorithm K Model
1
Mbase Mrecessive Mdominant Mmult
ANOVA FO 997 91.6 4.1 3.9 0.4
FOCE 986 90.9 3.8 4.7 0.6
Wald FO 947 68.4 11.1 16.3 4.2
FOCE 876 83.0 5.8 9.8 1.4
LRT FO 976 50.3 18.7 17.0 14.0
FOCE 951 91.3 4.0 3.5 1.2
AIC FO 999 14.9 23.2 22.4 39.5
FOCE 970 42.2 22.4 21.3 14.1
AICc FO 999 17.4 24.4 32.2 35.0
FOCE 970 48.3 20.7 20.1 9.9
CAIC FO 999 63.0 16.6 14.5 5.9
FOCE 970 95.3 2.1 2.5 0.1
BIC FO 999 55.7 19.6 16.6 8.1
FOCE 970 93.3 3.1 3.0 0.6
BICc FO 999 44.6 21.7 20.0 13.7
FOCE 970 85.6 7.0 6.0 1.2
K is the number of data sets on which the test could be performed.
 
1 M :          1  (CC CT TT) model with no gene effect.base {β 0 = β 1 = β 2 = } = =
M :       1,    1  (CC  CT  TT), reduced model.recessive {β 0 = β 1 = β 2 ≠ } = ≠
M :    1,       1  (CC  CT  TT), reduced model.dominant {β 0 = β 1 = β 2 ≠ } ≠ =
M :    1,       1  (CC  CT  TT), complete model.mult {β 0 = β 1 ≠ β 2 ≠ } ≠ ≠
J Biopharm Stat. Author manuscript
Page /13 13
Table 4
Percentage of data sets simulated under H  with N  40 for which each model is selected.1 =
Method Algorithm K Model
1
Mbase Mrecessive Mdominant Mmult
ANOVA FO 995 25.5 44.8 21.0 8.7
FOCE 968 22.3 43.3 25.5 8.9
Wald FOCE 878 17.9 41.7 32.7 7.7
LRT FOCE 923 19.1 47.3 20.5 13.1
AIC FOCE 962 1.3 31.1 13.1 54.5
AICc FOCE 962 1.6 35.1 14.7 48.6
CAIC FOCE 962 28.1 48.5 19.9 3.5
BIC FOCE 962 21.6 50.3 21.7 6.4
BICc FOCE 962 11.5 51.7 33.1 13.7
K is the number of data sets on which the test could be performed.
 
1 M :          1  (CC CT TT) model with no gene effect.base {β 0 = β 1 = β 2 = } = =
M :       1,    1  (CC  CT  TT), reduced model.recessive {β 0 = β 1 = β 2 ≠ } = ≠
M :    1,       1  (CC  CT  TT), reduced model.dominant {β 0 = β 1 = β 2 ≠ } ≠ =
M :    1,       1  (CC  CT  TT), complete model.mult {β 0 = β 1 ≠ β 2 ≠ } ≠ ≠
Results obtained with FO are not presented for these strategies because of their poor performance under H0 ( ).table 3
